All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Thomas Cluzeau, Centre Hospitalier Universitaire de Nice, Nice, FR. We asked: Is azacitidine + APR-246 safe and effective in patients with TP53 mutated MDS and acute myeloid leukemia?
Is azacitidine + APR-246 safe and effective in TP53 mutated MDS and AML?
Results from the phase II study, evaluating the novel p53-activating drug, APR-246, + azacitidine for the treatment of patients with TP53 mutated MDS and acute myeloid leukemia, were presented at this year's EHA meeting. The combination has demonstrated a manageable toxicity profile and promising clinical efficacy in this setting.
Subscribe to get the best content related to MDS delivered to your inbox